• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

儿童哮喘一级预防的成本效益:一项决策分析模型

Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model.

作者信息

Ramos G Feljandro P, van Asselt Antoinette D I, Kuiper Sandra, Severens Johan L, Maas Tanja, Dompeling Edward, Knottnerus J André, van Schayck Onno C P

机构信息

Department of General Practice, CAPHRI School for Public Health and Primary Care, Maastricht University, P.O. Box 616, 6200 MD, Maastricht, The Netherlands,

出版信息

Eur J Health Econ. 2014 Nov;15(8):869-83. doi: 10.1007/s10198-013-0532-x. Epub 2013 Oct 6.

DOI:10.1007/s10198-013-0532-x
PMID:24096902
Abstract

BACKGROUND

Many children stand to benefit from being asthma-free for life with primary (i.e., prenatally started) prevention addressing one environmental exposure in a unifaceted (UF) approach or at least two in a multifaceted (MF) approach. We assessed the cost-effectiveness of primary prevention programmes for Dutch children in a decision-analytic framework.

METHODS

A decision-analytic tree model analysing healthcare costs and asthma cases prevented was developed to compare usual care (UC) with two UF and three MF programmes on the primary prevention of asthma amongst children. Programmes were evaluated through incremental cost-effectiveness ratios and net monetary benefits. Decision and parameter uncertainty were subjected to value-of-information analyses.

RESULTS

The current UC and one of three MF programmes dominated the other alternatives. The MF programme was more costly but also more effective than UC at an incremental cost-effectiveness ratio of 8,209.20/additional asthma case prevented. The value of perfect information to reduce uncertainty was 291.6M at its lowest. Most of the uncertainty in the cost-effectiveness threshold was attributable to the probability and cost estimates for low-risk children.

CONCLUSION

This study supports the feasibility of a structured programme that simultaneously addresses exposure to house dust mites, pet dander, environmental tobacco, and breast-feeding as a cost-effective alternative to UC in the primary prevention of asthma amongst children.

摘要

背景

许多儿童有望通过初级预防(即从产前开始)终身摆脱哮喘,初级预防采用单因素(UF)方法应对一种环境暴露,或采用多因素(MF)方法应对至少两种环境暴露。我们在一个决策分析框架中评估了荷兰儿童初级预防项目的成本效益。

方法

开发了一个决策分析树模型,分析医疗保健成本和预防的哮喘病例,以比较常规护理(UC)与两个UF项目和三个MF项目在儿童哮喘初级预防方面的效果。通过增量成本效益比和净货币效益对项目进行评估。对决策和参数不确定性进行信息价值分析。

结果

当前的UC和三个MF项目中的一个优于其他方案。MF项目成本更高,但效果也比UC更好,增量成本效益比为每预防一例额外哮喘病例<8209.20欧元。降低不确定性的完美信息价值最低为2.916亿欧元。成本效益阈值的大部分不确定性归因于低风险儿童的概率和成本估计。

结论

本研究支持一项结构化项目的可行性,该项目同时应对屋尘螨暴露、宠物皮屑、环境烟草暴露和母乳喂养,作为儿童哮喘初级预防中UC的一种具有成本效益的替代方案。

相似文献

1
Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model.儿童哮喘一级预防的成本效益:一项决策分析模型
Eur J Health Econ. 2014 Nov;15(8):869-83. doi: 10.1007/s10198-013-0532-x. Epub 2013 Oct 6.
2
Structuring and validating a cost-effectiveness model of primary asthma prevention amongst children.构建并验证儿童哮喘初级预防的成本效益模型。
BMC Med Res Methodol. 2011 Nov 9;11:150. doi: 10.1186/1471-2288-11-150.
3
Cost effectiveness of vitamin c supplementation for pregnant smokers to improve offspring lung function at birth and reduce childhood wheeze/asthma.维生素 C 补充剂对吸烟孕妇的成本效益:改善出生时后代肺功能并减少儿童喘息/哮喘。
J Perinatol. 2018 Jul;38(7):820-827. doi: 10.1038/s41372-018-0135-6. Epub 2018 May 22.
4
Development of an economic model to assess the cost effectiveness of asthma management strategies.开发一种经济模型以评估哮喘管理策略的成本效益。
Pharmacoeconomics. 2002;20(3):183-94. doi: 10.2165/00019053-200220030-00004.
5
The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle cell disease: a systematic review and economic evaluation.儿童镰状细胞病的一级卒中预防的临床效果和成本效益:系统评价和经济评估。
Health Technol Assess. 2012;16(43):1-129. doi: 10.3310/hta16430.
6
Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.心血管疾病一级预防计划在基层医疗保健环境中的成本效益。EUROACTION 项目波兰部分的结果。
Kardiol Pol. 2013;71(7):702-11. doi: 10.5603/KP.2013.0157.
7
Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.巴雷特食管的监测:通过系统评价、专家研讨会和经济模型探索不确定性
Health Technol Assess. 2006 Mar;10(8):1-142, iii-iv. doi: 10.3310/hta10080.
8
Cost-utility analysis of orthoptic screening in kindergarten: a Markov model based on data from Germany.幼儿园斜视筛查的成本效用分析:基于德国数据的马尔可夫模型
Pediatrics. 2004 Feb;113(2):e95-108. doi: 10.1542/peds.113.2.e95.
9
A decision analytic model to investigate the cost-effectiveness of poisoning prevention practices in households with young children.一个用于研究预防幼儿家庭中毒措施成本效益的决策分析模型。
BMC Public Health. 2016 Aug 3;15:705. doi: 10.1186/s12889-016-3334-0.
10
Cost-Effectiveness Analysis in Telehealth: A Comparison between Home Telemonitoring, Nurse Telephone Support, and Usual Care in Chronic Heart Failure Management.远程医疗中的成本效益分析:家庭远程监测、护士电话支持与慢性心力衰竭管理中常规护理的比较。
Value Health. 2018 Jul;21(7):772-782. doi: 10.1016/j.jval.2017.11.011. Epub 2018 Mar 21.

引用本文的文献

1
Development of a conceptual model of childhood asthma to inform asthma prevention policies.制定儿童哮喘概念模型以制定哮喘预防政策。
BMJ Open Respir Res. 2021 Nov;8(1). doi: 10.1136/bmjresp-2021-000881.
2
Practical and Conceptual Considerations for the Primary Prevention of Asthma.实用与概念性考虑:哮喘的初级预防。
Clin Chest Med. 2019 Mar;40(1):1-11. doi: 10.1016/j.ccm.2018.10.002. Epub 2018 Dec 19.
3
Asthma.哮喘。

本文引用的文献

1
Structuring and validating a cost-effectiveness model of primary asthma prevention amongst children.构建并验证儿童哮喘初级预防的成本效益模型。
BMC Med Res Methodol. 2011 Nov 9;11:150. doi: 10.1186/1471-2288-11-150.
2
Prevention of asthma in genetically susceptible children: a multifaceted intervention trial focussed on feasibility in general practice.预防遗传易感儿童哮喘:一项多方面干预试验,重点关注在全科医学中的可行性。
Pediatr Allergy Immunol. 2011 Dec;22(8):794-802. doi: 10.1111/j.1399-3038.2011.01192.x. Epub 2011 Jul 13.
3
Mono and multifaceted inhalant and/or food allergen reduction interventions for preventing asthma in children at high risk of developing asthma.
Nat Rev Dis Primers. 2015 Sep 10;1(1):15025. doi: 10.1038/nrdp.2015.25.
用于预防哮喘高危儿童患哮喘的单一及多方面吸入性和/或食物过敏原减少干预措施。
Cochrane Database Syst Rev. 2009 Jul 8(3):CD006480. doi: 10.1002/14651858.CD006480.pub2.
4
Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.经济评估中的敏感性分析:对英国国家卫生与临床优化研究所当前实践的审核及其在决策中的应用与价值综述
Health Technol Assess. 2009 Jun;13(29):iii, ix-xi, 1-61. doi: 10.3310/hta13290.
5
Exploring uncertainty in cost-effectiveness analysis.探索成本效益分析中的不确定性。
Pharmacoeconomics. 2008;26(9):781-98. doi: 10.2165/00019053-200826090-00008.
6
Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI).最优成本效益决策:成本效益可接受性曲线(CEAC)、成本效益可接受性前沿(CEAF)以及完美信息期望值(EVPI)的作用。
Value Health. 2008 Sep-Oct;11(5):886-97. doi: 10.1111/j.1524-4733.2008.00358.x. Epub 2008 May 16.
7
The burden of illness experienced by young children associated with asthma: a population-based cohort study.幼儿哮喘相关疾病负担:一项基于人群的队列研究。
J Asthma. 2008 Jan-Feb;45(1):45-9. doi: 10.1080/02770900701815743.
8
Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide.药物经济学与卫生技术评估的建模方法:概述与指南
Pharmacoeconomics. 2008;26(2):131-48. doi: 10.2165/00019053-200826020-00004.
9
Modeling the impact of genetic screening technologies on healthcare: theoretical model for asthma in children.模拟基因筛查技术对医疗保健的影响:儿童哮喘的理论模型
Mol Diagn Ther. 2007;11(5):313-23. doi: 10.1007/BF03256252.
10
Interactive effect of family history and environmental factors on respiratory tract-related morbidity in infancy.家族病史与环境因素对婴儿期呼吸道相关发病率的交互作用。
J Allergy Clin Immunol. 2007 Aug;120(2):388-95. doi: 10.1016/j.jaci.2007.03.038. Epub 2007 May 10.